TrialJournal for immunotherapy of cancer2024

Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial.

Jing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.